Cysteine-Engineered Antibody Site-Specific Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for attaching cytotoxic drugs to antibodies result in heterogeneous mixtures due to multiple attachment sites, making it difficult to control reaction conditions and characterize the resulting antibody-drug conjugates, leading to instability and reduced efficacy.
Innovation Solution
Engineered antibodies with specific cysteine mutations (e.g., THIOMAB™ antibodies) that allow for site-specific conjugation of cytotoxic drugs, maintaining antibody stability and efficacy through controlled mutagenesis and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional methods are used to attach cytotoxic drugs to antibodies through multiple lysine residues, then the drug loading capacity increases, but the heterogeneity of the antibody-drug conjugate mixture increases and manufacturing precision deteriorates
Solution Approach 1:
The patent applies local quality by introducing specific cysteine mutations at predetermined positions on the antibody molecule. This creates localized reactive sites with unique properties (different pKa values and reactivities) that enable controlled, site-specific drug conjugation. The local modification of amino acid residues at specific positions allows for precise control of drug attachment while maintaining overall antibody structure and function.
Solution Approach 2:
The patent utilizes parameter changes by exploiting the different pKa values and reactivities of cysteine thiols at various positions on the antibody. By adjusting reaction conditions (pH, temperature, reagent concentration) to match the specific properties of each cysteine residue, the patent achieves controlled conjugation at predetermined sites. This allows for precise control of drug loading stoichiometry and eliminates the heterogeneity associated with conventional random conjugation methods.
2Quantity of substance
If multiple cysteine residues are engineered into the antibody for drug conjugation, then the drug loading capacity increases, but the stability of the antibody structure deteriorates due to potential misfolding or disulfide bond formation
Solution Approach 1:
The patent introduces cysteine mutations at specific local positions on the antibody that are strategically chosen to minimize disruption to the overall protein structure. These localized modifications are positioned in regions where they are less likely to interfere with critical disulfide bonds or cause misfolding, thereby maintaining antibody structural stability while enabling controlled drug conjugation.
Solution Approach 2:
The patent uses maleimide-containing linkers as intermediaries between the engineered cysteine residues and the cytotoxic drugs. This intermediary approach allows for controlled, stepwise conjugation: first the maleimide reacts specifically with the engineered cysteine thiols under controlled conditions, then the drug is attached to the maleimide-cysteine adduct. This two-step process minimizes unwanted side reactions and maintains antibody stability throughout the conjugation process.
3Manufacturing precision
If site-specific cysteine conjugation is implemented, then manufacturing precision and homogeneity improve, but the device complexity increases due to engineered mutations and controlled expression
Solution Approach 1:
The patent simplifies the engineering process by utilizing the natural variation in pKa values and reactivities of cysteine residues at different positions. By selecting cysteine mutation sites with distinctly different pKa values, the patent achieves orthogonal reactivity patterns that allow for controlled conjugation without requiring complex additional engineering. This approach to parameter-based differentiation simplifies the overall process while maintaining high manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cysteine-engineered antibodies achieve uniform stoichiometry and enhanced stability, maintaining antigen binding and effector functions while allowing for targeted drug delivery, demonstrating improved in vitro and in vivo performance compared to conventional ADCs.
Implementation Method 1
Cysteine thiols are reactive at neutral pH, unlike most amines which are protonated and less nucleophilic near pH 7. Since free thiol (RSH, sulfhydryl) groups are relatively reactive, proteins with cysteine residues often exist in their oxidized form as disulfide-linked oligomers or have internally bridged disulfide groups. Antibody cysteine thiol groups are generally more reactive, i.e. more nucleophilic, towards electrophilic conjugation reagents than antibody amine or hydroxyl groups.
Data Source
AI summary
Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.